Author
Manjulika Gautam, Prof. Udai Pratap Singh, Dr. Rohini Khurana, Anju Pandey
Keywords
Natural vitamin C intake, Head and neck cancer, Quality of life, EORTC QLQ
Abstract
Alternative medicines are most sought after directions when the patients are diagnosed with high grade carcinomas. The rise in the use of dietary supplements and herbal medications by patients makes it imperative to re-evaluate the past findings of clinical studies. Among unconventional approaches, high dose vitamin C is one of the most widely used and studied, yet controversial approaches. In case of the high-symptom burden and high morbidity, evaluation of quality of life (QOL) becomes important. The study therefore evaluates the impact of intake of 120mg/day vitamin C from natural sources on quality of life of head and neck cancer patients (N=20) at a tertiary care centre located in Lucknow. The responses were obtained using the bilingual EORTC QLQ-C30 (version3.0) and EORTC QLQ-HN35 (version 1.0). The results obtained from dependent sample t-test reveal that oral intake of vitamin C from natural sources can be helpful in providing relief from constipation and problems related to teeth. The study suggests that the oral intake can be helpful in mitigation of cancer and further research should be done as to determine the further applicability of vitamin C in treatment of cancer.
References
[1] Aaronson NK, A. S. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. . Journal of the National Cancer Institute , 365-376.
[2] Aaronson NK, A. S. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. . Journal of the National Cancer Institute , 365-376.
[3] Cloos PA, C. J. (2008). Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev , 1115-1140.
[4] Dua, J., Cullena, J. J., & Buethnera, G. R. (2012). Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim Biophys Acta , 443-457.
[5] FA., H. (1985). Micronutrient requirements of cancer patients. . Cancer , 295–300.
[6] Fain O, P. J. (2003). Hypovitaminosis C in hospitalized patients. Eur J Intern Med . , ;419–25.
[7] Fayers PM, A. N. (2001). The EORTC QLQ-C30 Scoring Manual (3rd Edition). . Brussels: European Organisation for Research and Treatment of Cancer.
[8] Jonas CR, P. A. (2000). Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr , 181–90.
[9] Ki, B., & Mead, M. N. (2003). Vitamin C in alternative cancer treatment: historical background. Inteqr Cancer Ther , 147-54.
[10] Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018). Intravenous vitamin C in the supportive care of cancer patients:a review and rational approach. Current Oncology, 139-148.
[11] Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018). Intravenous vitamin C in the supportive care of cancer patients:a review and rational approach.Current Oncology , 139-148.
[12] Levine M, C.-C. C. (1996). Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A , 3704-3709.
[13] Lu H, D. C. (2005). Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem , 41928–41939.
[14] Mandl J, S. A. (2009). Vitamin C: update on physiology and pharmacology. Br J Pharmacol. , 1097-110.
[15] Mata, A. d., Carvalho, R. d., Alencar, M. d., Carvalho Melo CavalCante, A. d., & da silva, B. B. (2016). Ascorbic acid in the prevention and treatment of cancer. Rev Assoc Med Bras , 680-686.
[16] Mayland CR, B. M. (2005.). Vitamin C deficiency in cancer patients. Palliat Med , 17–20.
[17] Ohno, S., Chno, Y., Suzuki, N., Soma, G.-I., & Inoue, M. (2009). High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer. International journal of Cancer research and treatment , 809-815.
[18] Park, S. (2013, September 9). The Effects of High Concentrations of Vitamin C on Cancer Cells. Nutrients , 3496-3505.
[19] Romney SL, B. J. (1987;.). Plasma reduced and total ascorbic acid in human uterine cervix dysplasia and cancer.Ann NY Acad Sci, 132-43.
[20] S., M. (2003). Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr , 933S–40S.
[21] Wilson, M. K., Baguley, B. C., Wall, C., Jameson, M. B., & Findlay, M. P. (2014). Review of high-dose intravenous vitamin C as an anticancer agent. Asia-Pacific Journal of Clinical Oncology , 22-37.
[22] Yeom CH, J. G. (2007). Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci . , 7–11.
[2] Aaronson NK, A. S. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. . Journal of the National Cancer Institute , 365-376.
[3] Cloos PA, C. J. (2008). Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev , 1115-1140.
[4] Dua, J., Cullena, J. J., & Buethnera, G. R. (2012). Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim Biophys Acta , 443-457.
[5] FA., H. (1985). Micronutrient requirements of cancer patients. . Cancer , 295–300.
[6] Fain O, P. J. (2003). Hypovitaminosis C in hospitalized patients. Eur J Intern Med . , ;419–25.
[7] Fayers PM, A. N. (2001). The EORTC QLQ-C30 Scoring Manual (3rd Edition). . Brussels: European Organisation for Research and Treatment of Cancer.
[8] Jonas CR, P. A. (2000). Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr , 181–90.
[9] Ki, B., & Mead, M. N. (2003). Vitamin C in alternative cancer treatment: historical background. Inteqr Cancer Ther , 147-54.
[10] Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018). Intravenous vitamin C in the supportive care of cancer patients:a review and rational approach. Current Oncology, 139-148.
[11] Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018). Intravenous vitamin C in the supportive care of cancer patients:a review and rational approach.Current Oncology , 139-148.
[12] Levine M, C.-C. C. (1996). Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A , 3704-3709.
[13] Lu H, D. C. (2005). Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem , 41928–41939.
[14] Mandl J, S. A. (2009). Vitamin C: update on physiology and pharmacology. Br J Pharmacol. , 1097-110.
[15] Mata, A. d., Carvalho, R. d., Alencar, M. d., Carvalho Melo CavalCante, A. d., & da silva, B. B. (2016). Ascorbic acid in the prevention and treatment of cancer. Rev Assoc Med Bras , 680-686.
[16] Mayland CR, B. M. (2005.). Vitamin C deficiency in cancer patients. Palliat Med , 17–20.
[17] Ohno, S., Chno, Y., Suzuki, N., Soma, G.-I., & Inoue, M. (2009). High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer. International journal of Cancer research and treatment , 809-815.
[18] Park, S. (2013, September 9). The Effects of High Concentrations of Vitamin C on Cancer Cells. Nutrients , 3496-3505.
[19] Romney SL, B. J. (1987;.). Plasma reduced and total ascorbic acid in human uterine cervix dysplasia and cancer.Ann NY Acad Sci, 132-43.
[20] S., M. (2003). Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr , 933S–40S.
[21] Wilson, M. K., Baguley, B. C., Wall, C., Jameson, M. B., & Findlay, M. P. (2014). Review of high-dose intravenous vitamin C as an anticancer agent. Asia-Pacific Journal of Clinical Oncology , 22-37.
[22] Yeom CH, J. G. (2007). Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci . , 7–11.
Received : 15 January 2020
Accepted : 14 July 2020
Published : 26 July 2020
DOI: 10.30726/esij/v7.i3.2020.73017